We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





First-of-Its-Kind SARS-CoV-2 Antibody Testing System Tests Both Anti-Nucleocapsid and Anti-Spike Antibodies in One Reaction

By LabMedica International staff writers
Posted on 04 Oct 2021

A new high-throughput SARS-CoV-2 antibody testing system could become the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction. More...

SCIENION (Berlin, Germany) has entered into a strategic collaboration with Pictor Limited (Auckland, New Zealand) to commercialize the new high throughput SARS-CoV-2 antibody testing system. The two companies will incorporate SCIENION’s CL2 sciREADER system into Pictor’s PictArray SARS-CoV-2 Serology Test to create the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction. This analysis will be key to support the sustained fight against COVID-19 by measuring a population’s level of herd immunity through natural infections and vaccinations.

The combined system will provide a highly automated miniaturized multiplex immunoassay test in a 96 well plate format capable of providing quick analysis on patients’ level of antibodies. The system also leverages proprietary software, developed by Pictor, which produces a risk score for individuals to determine their likelihood of carrying a COVID-19 infection. The PictArray SARS-CoV-2 Serology Test is slated to soon enter clinical trials with the goal of receiving FDA emergency use authorization (EUA) and brought to market in early 2022. The companies also plan to pursue a positive Committee for Medicinal Products for Human Use (CHMP) opinion for use in the UK and EU.

“As COVID-19 remains a widespread concern, measuring antibody levels across populations will be critical for public health officials to stop new variant surges,” said Holger Eickhoff Ph.D., co-founder and CEO of SCIENION GmbH. “We’re honored to work with Pictor to help further develop this vital technology.”

“We are thrilled to have entered into this strategic collaboration with SCIENION,” said Pictor CEO Thomas Schlumpberger. “Leveraging the sciREADER colormetric high performance and accuracy enables Pictor to bring high throughput, high performance and low-cost multiplexed antibody testing for SARS-CoV-2 to the market. We are eager to provide insights into the epidemiological spread of the virus to help inform control and prevention measures.”

Related Links:
SCIENION 
Pictor Limited 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.